학술논문
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
Document Type
Article
Author
Bethge, WA; Martus, P; Schmitt, M; Holtick, U; Subklewe, M; von Tresckow, B; Ayuk, F; Wagner-Drouet, EM; Wulf, G; Marks, R; Penack, O; Schnetzke, U; Koenecke, C; von Bonin, M; Stelljes, M; Glass, B; Baldus, CD; Vucinic, V; Mougiakakos, D; Topp, M; Fante, M; Schroers, R; Bayir, L; Borchmann, P; Buecklein, V; Hasenkamp, J; Hanoun, C; Thomas, S; Beelen, D; Lengerke, C; Kroeger, N; Dreger, P
Source
Blood; 20240101, Issue: Preprints
Subject
Language
ISSN
00064971; 15280020
Abstract
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as new standard-of-care (SOC) treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR-T cell therapies with the aim to explore risk factors associated with outcome.